公开(公告)号：US20230181540A1

公开(公告)日：2023-06-15

申请号：US17925188

申请日：2021-05-20

Applicant: Wylder Nation Foundation

Inventor： Edward H. SCHUCHMAN ,  Calogera M. SIMONARO

IPC: A61K31/426 ,  A61K31/4155 ,  A61K31/421 ,  A61K31/429 ,  A61P3/00

CPC classification number: A61K31/426 ,  A61K31/421 ,  A61K31/429 ,  A61K31/4155 ,  A61P3/00

Abstract: The present invention provides, inter alia, compositions, methods, and diagnostics for using CB2 cannabinoid receptor agonists for treating and preventing lysosomal storage disorders.

公开(公告)号：US20250057838A1

公开(公告)日：2025-02-20

申请号：US18667468

申请日：2024-05-17

Applicant: Wylder Nation Foundation

Inventor： Maria Dolores LEDESMA ,  Adrian BARTOLL ,  Edward H. SCHUCHMAN

IPC: A61K31/501 ,  A61K9/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/232 ,  A61K31/325 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/573 ,  A61K35/28 ,  A61K45/06 ,  A61P1/00 ,  A61P25/28 ,  C12N9/16

Abstract: The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

公开(公告)号：US12023332B2

公开(公告)日：2024-07-02

申请号：US16977772

申请日：2019-03-05

Applicant: Wylder Nation Foundation

Inventor： Maria Dolores Ledesma ,  Adrian Bartoll ,  Edward H. Schuchman

IPC: A61K31/501 ,  A61K9/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/232 ,  A61K31/325 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/573 ,  A61K35/28 ,  A61K45/06 ,  A61P1/00 ,  A61P25/28 ,  C12N9/16

CPC classification number: A61K31/501 ,  A61K9/0085 ,  A61K31/16 ,  A61K31/164 ,  A61K31/232 ,  A61K31/325 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/573 ,  A61K35/28 ,  A61K45/06 ,  A61P1/00 ,  A61P25/28 ,  C12N9/16 ,  C12Y301/04012

Abstract: The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.

公开(公告)号：US20210085678A1

公开(公告)日：2021-03-25

申请号：US16977772

申请日：2019-03-05

Applicant: Wylder Nation Foundation

Inventor： Maria Dolores LEDESMA ,  Adrian BARTOLL ,  Edward H. SCHUCHMAN

IPC: A61K31/501 ,  A61P1/00 ,  A61K31/164 ,  A61K31/232 ,  A61K31/415 ,  C12N9/16 ,  A61K9/00 ,  A61K35/28 ,  A61K31/4545 ,  A61K31/16 ,  A61K31/573 ,  A61K45/06 ,  A61P25/28 ,  A61K31/4164 ,  A61K31/496 ,  A61K31/325

Abstract: The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.